Abstract 360P
Background
Breast cancer is the the most frequently diagnosed cancer worldwide in women, with nearly two million new cases diagnosed in 2018. In the Philippines, breast cancer is the most common cancer among women. Upon diagnosis, the decision process differs from person to person. The patients then meet choices about surgical treatment and the need for adjuvant treatment, taking into consideration surgery, chemotherapy and radiation therapy to name a few. However, these decisions are not clear cut and a thorough discussion between the patient and the physician regarding treatment options taking into consideration the choice of the patient. This study aims to identify factors influencing treatment decisions among breast cancer patients in the Philippine General Hospital Cancer Institute - Medical Oncology Outpatient Clinic.
Methods
The study used a questionnaire and structured interview adapted from study done by Grunfeld, et.al. Descriptive statistics were utilized in the analysis of the data acquired from the recruited participants. This allowed identification of patient demographics, economic profile, cancer profile, sources of financial or medical assistance and summary of patient’s responses to identify the factors influencing treatment decisions among breast cancer patients.
Results
A total of 272 participants consented and included in the analysis of the study. This study identified high level of satisfaction with consultation to their attending physician, caring and sincere communication about prognosis and likelihood of benefit from treatment, family as person of influence, patient’s collaborative role in the decision-making process, desire of cure and trust with their doctors as factors of influence in accepting cancer treatment decisions.
Conclusions
Health practices and treatment decisions among Filipino breast cancer patients are widely affected by interplay of the following factors: family, community, doctor’s recommendations, patient’s satisfaction and participation in the decision-making, health care access and adverse treatments to name a few.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bobby de Guzman.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract